• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

    2/8/24 10:14:32 AM ET
    $MRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRTX alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2 )*

                

    Mirati Therapeutics, Inc.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    60468T105


    (CUSIP Number)

    December 29, 2023


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 60468T105

    1. NAMES OF REPORTING PERSONS

    Wellington Management Group LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Massachusetts

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 60468T105

    1. NAMES OF REPORTING PERSONS

    Wellington Group Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%
    12. TYPE OF REPORTING PERSON

    HC


    CUSIP No. 60468T105

    1. NAMES OF REPORTING PERSONS

    Wellington Investment Advisors Holdings LLP
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 0
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 0
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.00%
    12. TYPE OF REPORTING PERSON

    HC

    Item 1.
    (a) Name of Issuer
    Mirati Therapeutics, Inc.
    (b) Address of Issuer's Principal Executive Offices
    3545 Cray Court
    San Diego, CA 92121
    Item 2.
    (a) Name of Person Filing
    Wellington Management Group LLP
    Wellington Group Holdings LLP
    Wellington Investment Advisors Holdings LLP
    (b) Address of Principal Business Office or, if None, Residence
    c/o Wellington Management Company LLP
    280 Congress Street
    Boston, MA 02210
    (c) Citizenship
    Wellington Management Group LLP - Massachusetts
    Wellington Group Holdings LLP - Delaware
    Wellington Investment Advisors Holdings LLP - Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    60468T105
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    If this statement is filed pursuant to Rule 13d-1(c), check this box [ ]
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    See the responses to Item 9 on the attached cover pages.
    (b) Percent of Class:
    See the responses to Item 11 on the attached cover pages.
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 0
    (ii) shared power to vote or to direct the vote See the responses to Item 6 on the attached cover pages.
    (iii) sole power to dispose or to direct the disposition of 0
    (iv) shared power to dispose or to direct the disposition of See the responses to Item 8 on the attached cover pages.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The securities as to which this Schedule is filed are owned of record by clients of one or more investment advisers identified in Exhibit A directly or indirectly owned by Wellington Management Group LLP. Those clients have the right to receive, or the power to direct the receipt of, dividends from, or the proceeds from the sale of, such securities. No such client is known to have such right or power with respect to more than five percent of this class of securities, except as follows:

    Not Applicable.
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

    See attached Exhibit A.
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.
    Item 9. Notice of Dissolution of Group.

    Not Applicable.
    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024


    Exhibit A

    Pursuant to the instructions in Item 7 of Schedule 13G, the following lists the identity and Item 3 classification of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

    Wellington Group Holdings LLP – HC
    Wellington Investment Advisors LLP – HC
    Wellington Management Global Holdings, Ltd. - HC

    One or more of the following investment advisers (the “Wellington Investment Advisers”):

    Wellington Management Company LLP – IA
    Wellington Management Canada LLC – IA
    Wellington Management Singapore Pte Ltd – IA
    Wellington Management Hong Kong Ltd – IA
    Wellington Management International Ltd – IA
    Wellington Management Japan Pte Ltd – IA
    Wellington Management Australia Pty Ltd - IA

    The securities as to which this Schedule is filed by Wellington Management Group LLP, as parent holding company of certain holding companies and the Wellington Investment Advisers, are owned of record by clients of the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP controls directly, or indirectly through Wellington Management Global Holdings, Ltd., the Wellington Investment Advisers. Wellington Investment Advisors Holdings LLP is owned by Wellington Group Holdings LLP. Wellington Group Holdings LLP is owned by Wellington Management Group LLP.


    EXHIBIT B

    JOINT FILING AGREEMENT

    The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Mirati Therapeutics, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate. It is understood and agreed that the joint filing of the Schedule 13G shall not be construed as an admission that the persons named herein constitute a group for purposes of Regulation 13D-G of the Securities Exchange Act of 1934, nor is a joint venture for purposes of the Investment Company Act of 1940.


    By: Wellington Management Group LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Group Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    By: Wellington Investment Advisors Holdings LLP
    By: /s/ Taisia Lowe
    Name: Taisia Lowe
    Title: Regulatory Analyst
    Date: February 14, 2024

    Get the next $MRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$51.00 → $48.00Neutral → Buy
    Citigroup
    8/9/2023$45.00Neutral → Buy
    B. Riley Securities
    8/9/2023$45.00Overweight
    Piper Sandler
    7/27/2023Sector Underperform
    Scotiabank
    5/25/2023Perform → Outperform
    Oppenheimer
    12/14/2022Hold
    Needham
    12/9/2022$121.00 → $53.00Buy → Neutral
    Citigroup
    12/8/2022$110.00 → $59.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $MRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mirati Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $48.00 from $51.00 previously

      8/10/23 7:25:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $45.00

      8/9/23 8:29:32 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Mirati Therapeutics with a new price target

      Piper Sandler resumed coverage of Mirati Therapeutics with a rating of Overweight and set a new price target of $45.00

      8/9/23 7:36:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mirati Therapeutics Inc.

      SC 13G - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 4:21:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 2:51:56 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 9:13:21 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director

      SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher. "I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer." Dr. Gallagher has over 30 years of strategic, commercial, business development and drug dev

      6/23/23 4:00:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

      Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice pr

      11/8/22 4:05:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

      - Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors. Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently President, Chief Medical Officer, and a Board Member of Medikine. Prior to Medikine, he was Executive Vice President a

      10/4/22 4:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Financials

    Live finance-specific insights

    See more
    • Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

      Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in MTAP-deleted cancers demonstrating favorable safety profile and early signs of strong clinical activity David Meek to depart Company, Charles M. Baum, M.D., Ph.D., President and Founder, to assume role of interim CEO during search for permanent CEO Company will announce financial results for the second quarter 2023 along with recent corporate updates during a conference call at 5:30 p.m. ET / 2:30 p.m. PT SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASD

      8/8/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023

      SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 8, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 6674271. A replay of the call will be available approximately 2 hours after

      7/25/23 4:30:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

      SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates. "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales for KRAZATI®, which we believe is the best-in-class KRASG12C inhibitor. This is just the beginning of our journey with KRAZATI®, as we continue to advance our broad development plan in lung cancer and across other indications and lines of therapy," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "In add

      5/9/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

      SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previ

      1/10/24 8:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

      SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). "Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both durati

      11/2/23 7:30:00 AM ET
      $KURA
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

      Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati's Promising Pipeline Includes a Potent Selective PRMT5/MTA Inh

      10/8/23 5:16:00 PM ET
      $BMY
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for KRAZATI issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/14/22 7:40:10 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/12/22 6:09:02 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Efficacy

      12/12/22 4:56:01 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Boxer Capital, Llc returned 6,859,544 shares to the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/25/24 4:32:24 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cherrington Julie M returned 11,252 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:07 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharp Shalini returned 16,222 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:09 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Mirati Therapeutics Inc.

      15-12G - Mirati Therapeutics, Inc. (0001576263) (Filer)

      2/2/24 4:05:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:14 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:09 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care